To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.

Completed

Conditions studied: Rheumatoid Arthritis

In brief

To estimate the efficacy of treatment with TNFi as monotherapy or combination therapy with MTX and compare and contrast efficacy with Tofacitinib as monotherapy and combination therapy in a real world setting.

Key facts

Study ID

NCT05576051

Run by

Pfizer

People needed

9159

Starts

2015-06-04

Expected to finish

2015-10-07

Last updated by the study team

2025-12-23

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• RA patients in Corrona initiating a TNFi biologic (adalimumab, etanercept, infliximab, golimumab, certolizumab pegol) during follow-up in Corrona with no prior use of Tofacitinib

You may not qualify if…

• Patients with no history of cDMARD but history of 1+ biologics - these cases will be excluded from analyses
• Patients using combination therapy with a cDMARD other than MTX will be excluded
• Patients using combination therapy of MTX and another cDMARD will be excluded

Where it is running

• Pfizer — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.